A Rare Complication in a Patient Receiving Rivaroxaban: Alveolar Hemorrhage

Kılıç, Salih; Saraçoğlu, Erhan; Alkan, Gülin

doi:10.5543/tkda.2017.53919

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…61 Most reports of alveolar hemorrhage in the literature are secondary to warfarin, although newer direct oral anticoagulants (DOACs) have been associated with it. [71][72][73] A case series identified the incidence of rivaroxaban associated with significant alveolar hemorrhage to be 3 in 1,000 patients. 74 Several factors may be contributing to warfarin-induced hemoptysis.…”

Section: Ac-induced Lthmentioning

confidence: 99%

Life-Threatening Hemoptysis

Deshwal

Sinha

Mehta

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Life-threatening hemoptysis (LTH) is any amount of hemoptysis that causes significant hemodynamic decompensation or respiratory distress which may lead to death if left untreated. While the amount of hemoptysis that qualifies as massive hemoptysis has continued to be debated, any amount between 100 to 1,000 mL/day is considered significant. Up to 15% cases of hemoptysis are LTH and need urgent life-saving intervention. Understanding of pulmonary vascular anatomy is of paramount importance to manage LTH. The goal of treatment lies in airway protection, appropriate oxygenation, and prevention of exsanguination. Once the airway is stabilized, a quick diagnosis and control of bleeding site is targeted. This chapter highlights current practices and approach to LTH including medical management, bronchoscopic approach, and advanced therapies such as bronchial artery embolization and surgical resection. We review situations, such as bronchiectasis, vascular malformation, diffuse alveolar hemorrhage, and tracheostomy bleed and specific approach to management of these conditions in a systematic and evidence-based manner.

show abstract

Section: Ac-induced Lthmentioning

confidence: 99%

Life-Threatening Hemoptysis

Deshwal

Sinha

Mehta

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications

et al. 2022

View full text Add to dashboard Cite

Patient: Male, 80-year-old Final Diagnosis: Diffuse alveolar hemorrhage Symptoms: Dyspnea Medication:— Clinical Procedure: — Specialty: General and Internal Medicine Objective: Unusual clinical course Background: Diffuse alveolar hemorrhage (DAH) caused by direct oral anticoagulants (DOACs) has increased in recent years with the increase in prescriptions of DOACs. Generally, DOACs are considered to have a lower bleeding risk than the traditional anticoagulant, warfarin. However, major bleeding, including DAH, due to DOACs can be seen in clinical practice, and there are few reports to elucidate when DOAC-associated alveolar hemorrhage occurs and whether DOAC-induced DAH has a trigger. Case Report: An 80-year-old man diagnosed and treated for atrial fibrillation with apixaban 2.5 mg twice daily for 1 year before admission, underwent 2 invasive medical procedures over a short period of time. Hemoptysis began after the procedures. He experienced shortness of breath and rapidly progressive hypoxic respiratory failure. His postsurgical oxygen saturation level dropped rapidly. Chest radiography and computed tomography images showed pulmonary infiltration and ground-glass opacity in both lungs. Apixaban treatment was discontinued, and mechanical ventilation was initiated. Bronchoalveolar lavage cytology revealed hemosiderin-laden macrophages. A diagnosis of diffuse alveolar hemorrhage (DAH) was made. In previous reports about DAH caused by DOACs, most patients had bleeding triggers; drug interactions in patients taking DOACs are one of such triggers. Although DOACs are relatively safe for elderly patients, DAH can occur in patients receiving either early-stage or long-term treatment. Conclusions: The onset of DOAC-associated DAH is not limited to the early stages of medication initiation. Various triggers can induce DAH in patients receiving DOACs.

show abstract

A Rare Complication in a Patient Receiving Rivaroxaban: Alveolar Hemorrhage

Cited by 2 publications

References 0 publications

Life-Threatening Hemoptysis

Life-Threatening Hemoptysis

Apixaban-Associated Diffuse Alveolar Hemorrhage in an Elderly Man with Multiple Complications

Contact Info

Product

Resources

About